Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LOVENOX vs ENOXAPARIN SODIUM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Low molecular weight heparin (LMWH) that binds to antithrombin III, enhancing its inhibition of factor Xa and thrombin, thereby preventing thrombus formation.
Enoxaparin binds to antithrombin III (ATIII) via its pentasaccharide sequence, enhancing ATIII-mediated inhibition of factor Xa and, to a lesser extent, factor IIa (thrombin). It preferentially inhibits factor Xa over thrombin (anti-Xa:anti-IIa ratio ~3.6:1).
Treatment of deep vein thrombosis (DVT),Prevention of DVT in abdominal surgery, hip replacement, knee replacement, or medical patients with restricted mobility,Treatment of unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI) when administered with aspirin,Extended treatment of DVT in cancer patients (off-label)
Prophylaxis of deep vein thrombosis (DVT) in abdominal or hip/knee replacement surgery,Prophylaxis of DVT in medical patients with acute illness and restricted mobility,Inpatient treatment of acute DVT with or without pulmonary embolism (PE) when administered with warfarin,Outpatient treatment of acute DVT without PE when administered with warfarin,Unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI) when administered with aspirin,Acute ST-segment elevation myocardial infarction (STEMI) managed medically or with percutaneous coronary intervention (PCI)
1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg subcutaneously once daily for treatment of venous thromboembolism; 40 mg subcutaneously once daily for prophylaxis in abdominal surgery, hip or knee replacement; 30 mg subcutaneously every 12 hours for prophylaxis in medical patients; 0.5 mg/kg subcutaneously once daily for prophylaxis in patients with acute coronary syndrome.
1 mg/kg subcutaneous every 12 hours or 1.5 mg/kg subcutaneous once daily
Terminal half-life: 4.5-7 hours after subcutaneous administration; prolonged in renal impairment (up to 16 hours with Cr Cl <30 m L/min), requiring dose adjustment.
4.5-7 hours after single subcutaneous dose; prolonged to 8-12 hours in renal impairment (Cr Cl <30 m L/min). Clinical context: maintains anti-Xa activity for 12 hours with once-daily dosing.
Primarily metabolized in the liver by desulfation and depolymerization to lower molecular weight fragments with reduced anticoagulant activity.
Enoxaparin is partially metabolized in the liver via desulfation and depolymerization by heparanase and other enzymes. It has a complex pharmacokinetic profile with dose-dependent clearance; renal excretion accounts for elimination of active fragments and the unchanged drug.
Renal: 40-60% as active and inactive fragments via glomerular filtration and tubular secretion; biliary/fecal: minimal, <10%.
Renal (40-60% as unchanged drug via glomerular filtration and saturable tubular reabsorption). Biliary/fecal: negligible (<10%).
Antithrombin III (ATIII) binding: ~100% (enoxaparin is an ATIII-dependent inhibitor); nonspecific protein binding: negligible (<1%).
80% bound to antithrombin III (low affinity to other plasma proteins).
Vd: 0.1-0.2 L/kg; confined mainly to intravascular space, with limited extravascular distribution; reflects low tissue penetration.
0.04-0.06 L/kg (plasma volume distribution; low Vd indicates limited extravascular distribution).
Subcutaneous: 92-100% (nearly complete).
Subcutaneous: 90-92% (complete absorption).
For Cr Cl <30 m L/min: treatment dose 1 mg/kg subcutaneously once daily; prophylaxis dose 30 mg subcutaneously once daily. No adjustment for Cr Cl 30-50 m L/min but monitor closely.
Cr Cl < 30 m L/min: reduce dose to 1 mg/kg subcutaneous once daily
No specific dosing adjustment recommended for hepatic impairment based on Child-Pugh score; use with caution in severe hepatic impairment due to increased risk of bleeding.
No specific Child-Pugh based adjustment; use with caution in severe hepatic impairment due to increased bleeding risk
Prophylaxis: 0.5 mg/kg subcutaneously every 12 hours. Treatment: 1 mg/kg subcutaneously every 12 hours. Maximum single dose 120 mg. Weight must be >5 kg.
Neonates and infants: 1.5 mg/kg subcutaneous every 12 hours; Children < 2 months: 1.5 mg/kg every 12 hours; Children ≥ 2 months: 1 mg/kg every 12 hours
Elderly patients >75 years old: increased risk of bleeding; consider lower doses (e.g., 0.75 mg/kg every 12 hours for treatment) and monitor renal function closely; no specific dose adjustment solely by age but use with caution.
Increased risk of bleeding; consider lower doses (e.g., 0.5 mg/kg every 12 hours or 1 mg/kg once daily) and monitor renal function
Spinal/epidural hematomas may occur in patients anticoagulated with LMWH or heparinoids who receive neuraxial anesthesia or undergo spinal puncture. These hematomas can result in long-term or permanent paralysis.
Enoxaparin carries a black box warning for the risk of spinal or epidural hematomas in patients receiving neuraxial anesthesia or spinal puncture, which can result in long-term or permanent paralysis. Patients should be monitored for signs of neurological impairment, and concomitant use of drugs affecting hemostasis (e.g., NSAIDs, antiplatelet agents, other anticoagulants) increases the risk.
Risk of bleeding, especially with invasive procedures or concomitant use of antiplatelet agents,Heparin-induced thrombocytopenia (HIT) and heparin-induced thrombocytopenia with thrombosis (HITTS),Increased risk of spinal/epidural hematoma with neuraxial anesthesia,Use with caution in patients with renal impairment (creatinine clearance <30 m L/min) due to reduced clearance,Monitor for signs of bleeding and thrombocytopenia
Spinal/epidural hematoma risk with neuraxial anesthesia,Increased bleeding risk, especially in patients with renal impairment, thrombocytopenia, or age >65,Heparin-induced thrombocytopenia (HIT) risk; monitor platelet counts regularly,Use with caution in patients with severe renal impairment (Cr Cl <30 m L/min), as enoxaparin accumulates and increases bleeding risk; dose adjustment required,Not recommended in patients with mechanical heart valves, especially pregnant women, due to risk of valve thrombosis,Do not mix with other injections or infusions
Active major bleeding,History of heparin-induced thrombocytopenia (HIT),Hypersensitivity to enoxaparin, heparin, or pork products,Use of indwelling epidural catheter for analgesia or therapy
Active major bleeding or bleeding disorders (e.g., hemophilia, thrombocytopenic purpura),History of heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis (HITT),Hypersensitivity to enoxaparin, heparin, or pork products,Not recommended for use in patients with mechanical heart valves (especially pregnant women) due to risk of valve thrombosis,Concomitant use of other drugs that significantly increase bleeding risk (e.g., warfarin, aspirin, clopidogrel) without careful monitoring and indication
No specific food restrictions; avoid excessive alcohol consumption as it may increase bleeding risk.
No specific food interactions. However, foods high in vitamin K (e.g., leafy greens) may theoretically affect coagulation but are not clinically significant with enoxaparin. Avoid excessive alcohol intake due to potential bleeding risk. Maintain consistent diet if also taking warfarin.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. First trimester: No known increased risk of major malformations. Second/Third trimesters: Risk of maternal hemorrhage, placental abruption, and fetal hemorrhage due to anticoagulant effect. Use only if clearly needed.
Enoxaparin sodium does not cross the placenta and is not associated with teratogenicity in humans. However, there is a risk of hemorrhage during delivery. Use during pregnancy requires careful monitoring for bleeding.
Excreted in human milk in negligible amounts; M/P ratio not established. Considered compatible with breastfeeding; monitor infant for signs of bruising or bleeding.
Excretion into breast milk is minimal; M/P ratio not determined. Considered compatible with breastfeeding; no known adverse effects in nursing infants, but monitor for bleeding signs.
Renal blood flow increases during pregnancy, potentially increasing clearance. Dose adjustments may be needed in the third trimester based on anti-Xa monitoring. Standard prophylactic dose: 40 mg SC once daily; therapeutic dose: 1 mg/kg SC q12h. Consider weight-based dosing and monitor anti-Xa levels (target 0.5-1.0 IU/m L for therapeutic, 0.2-0.5 IU/m L for prophylaxis).
Pregnancy increases volume of distribution and clearance of enoxaparin, necessitating dose adjustment. Monitor anti-Xa levels and adjust dose to maintain target levels, typically requiring higher doses per weight in late pregnancy.
Enoxaparin is a low molecular weight heparin (LMWH) with predictable pharmacokinetics, eliminating the need for routine monitoring of anti-Xa activity in most patients. Dosing is based on weight and renal function; adjust for Cr Cl <30 m L/min (e.g., 30 mg once daily for VTE prophylaxis). Protamine sulfate partially reverses anticoagulant effect (60% neutralization). Avoid in patients with history of heparin-induced thrombocytopenia (HIT); check platelet counts every 2-3 days during therapy. Subcutaneous injection technique: administer in lateral abdominal wall, pinch skin, insert needle at 45-90° angle, do not rub site. Spinal/epidural hematoma risk with neuraxial anesthesia — remove indwelling catheter at least 12 hours after last prophylactic dose (24 hours for treatment doses).
Enoxaparin is a low molecular weight heparin (LMWH) that preferentially inhibits factor Xa over thrombin. Monitor anti-Xa levels in patients with renal impairment (Cr Cl <30 m L/min), obesity, or pregnancy. Avoid intramuscular injections and use with caution in patients receiving neuraxial anesthesia due to risk of spinal hematoma. Protamine sulfate partially reverses enoxaparin (up to 60% of anti-Xa activity). Does not routinely require monitoring of a PTT.
Inject enoxaparin exactly as prescribed; do not skip doses.,Rotate injection sites (left/right side of abdomen) to reduce bruising.,Do not massage the injection site after administration.,Watch for signs of bleeding: unusual bruising, black/tarry stools, pink/red urine, coughing up blood, or severe headache.,Seek emergency care for sudden back pain, numbness, or leg weakness (possible spinal hematoma).,Tell all healthcare providers you are taking this blood thinner before procedures or surgeries.,Use soft toothbrush and electric razor to minimize bleeding risk.,Avoid aspirin, NSAIDs, and other blood thinners unless prescribed by your doctor.
Inject subcutaneously as directed, rotating injection sites (e.g., left/right abdomen, alternating).,Do not massage the injection site after administration.,Report any signs of bleeding: unusual bruising, prolonged bleeding from cuts, blood in urine or stool, coughing up blood.,Seek immediate medical attention for symptoms of spinal hematoma after neuraxial procedure: back pain, numbness or weakness in legs, bowel/bladder dysfunction.,Inform all healthcare providers (including dentists) that you are taking enoxaparin.,Avoid NSAIDs, aspirin, or other blood thinners unless prescribed by your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LOVENOX vs ENOXAPARIN SODIUM, answered by our medical review team.
LOVENOX is a Low Molecular Weight Heparin that works by Low molecular weight heparin (LMWH) that binds to antithrombin III, enhancing its inhibition of factor Xa and thrombin, thereby preventing thrombus formation.. ENOXAPARIN SODIUM is a Low Molecular Weight Heparin that works by Enoxaparin binds to antithrombin III (ATIII) via its pentasaccharide sequence, enhancing ATIII-mediated inhibition of factor Xa and, to a lesser extent, factor IIa (thrombin). It preferentially inhibits factor Xa over thrombin (anti-Xa:anti-IIa ratio ~3.6:1).. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LOVENOX and ENOXAPARIN SODIUM depend on the specific clinical indication. These are both Low Molecular Weight Heparin agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LOVENOX is: 1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg subcutaneously once daily for treatment of venous thromboembolism; 40 mg subcutaneously once daily for prophylaxis in abdominal surgery, hip or knee replacement; 30 mg subcutaneously every 12 hours for prophylaxis in medical patients; 0.5 mg/kg subcutaneously once daily for prophylaxis in patients with acute coronary syndrome.. The standard adult dose of ENOXAPARIN SODIUM is: 1 mg/kg subcutaneous every 12 hours or 1.5 mg/kg subcutaneous once daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LOVENOX and ENOXAPARIN SODIUM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LOVENOX is classified as Category C. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. First trimester: No known increased risk of major malformations. Second/Third trimesters: Risk of materna. ENOXAPARIN SODIUM is classified as Category A/B. Enoxaparin sodium does not cross the placenta and is not associated with teratogenicity in humans. However, there is a risk of hemorrhage during delivery. Use during pregnancy requ. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.